BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd. is a regenerative engineering company specializing in advanced biologic products for bone and joint repair and restoration. The company develops and commercializes innovative solutions for cartilage and bone defect treatment, with a primary focus on minimally invasive surgical systems. RevoCart, their flagship product, is a one-step autologous cartilage repair system designed for surgically treating knee chondral and osteochondral defects using the patient's own cartilage tissue combined with a bioresorbable scaffold. The company also offers complementary products including OIF (Osteochondral Implant Facility) and SoufCut systems. BioGend's products target orthopedic surgeons and hospitals treating degenerative joint disease and sports-related cartilage injuries. The company has demonstrated international market presence, showcasing at major medical trade events including MEDICA 2023 in Germany and Medical Fair Asia 2024, as well as receiving recognition through awards such as the 2024 D&B Taiwan Top 1000 Elite SME Sustainability Excellence Award. Clinical documentation is available including Summary of Safety and Clinical Performance (SSCP) reports. The company serves both professional medical practitioners and patient populations.